Coronaviruses express a multifunctional papain-like protease, termed PLP2. PLP2 acts as 17 a protease that cleaves the viral replicase polyprotein, and a deubiquitinating (DUB) enzyme which 18 removes ubiquitin moieties from ubiquitin-conjugated proteins. Previous in vitro studies 19 implicated PLP2 DUB activity as a negative regulator of the host interferon (IFN) response, but 20 the role of DUB activity during virus infection was unknown. Here, we used X-ray structure-21 guided mutagenesis and functional studies to identify amino acid substitutions within the 22 ubiquitin-binding surface of PLP2 that reduced DUB activity without affecting polyprotein 23 processing activity. We engineered a DUB mutation (Asp1772 to Ala) into a murine coronavirus 24 and evaluated the replication and pathogenesis of the DUB mutant virus (DUBmut) in cultured 25 macrophages and in mice. We found that the DUBmut virus replicates similarly as the wild-type 26 virus in cultured cells, but the DUBmut virus activates an IFN response at earlier times compared 27 to the wild-type virus infection in macrophages, consistent with DUB activity negatively 28 regulating the IFN response. We compared the pathogenesis of the DUBmut virus to the wild-type 29 virus and found that the DUBmut-infected mice had a statistically significant reduction (p<0.05) 30 in viral titer in livers and spleens at day 5 post-infection, albeit both wild-type and DUBmut virus 31 infections resulted in similar liver pathology. Overall, this study demonstrates that structure-guided 32 mutagenesis aids the identification of critical determinants of PLP2-ubiquitin complex, and that 33 PLP2 DUB activity plays a role as an interferon antagonist in coronavirus pathogenesis.
Introduction
D1772A mutant compared to the wild-type enzyme. The wild-type enzyme normally interacts 126 strongly with Ub-AMC with a Km value of 0.67 µM. However, mutation of D1772 to an alanine 127 significantly disrupts the interaction with ubiquitin, making it impossible to saturate MHV PLP2 128 degree. A potential explanation for the observed selective disruption of ubiquitin binding stems 138 from our analysis of a primary sequence alignment of ubiquitin and ISG15 and the residues that 139 interact with D1772 (Fig. 2C) . The interaction between MHV PLP2 D1772 and the R42 residue in 140 human and mouse ubiquitin is absent in human and mouse ISG15 since this residue is a tryptophan 141 in human and mouse ISG15. Therefore, in line with our observations, D1772A mutation would 142 not be expected to alter ISG15 binding. In contrast to R42, residue R72 is conserved in both 143 ubiquitin and ISG15 and its interaction with MHV PLP2 for ubiquitin is likely weaker than that 144 with ISG15. 145 PLP2 D1772A mutant exhibits reduced DUB activity and inhibition of IFN response in cell 146 culture based assays. The in vitro biochemical studies presented here support the notion that we 147 are able to use a structure-guided mutagenesis to uncouple the DUB enzymatic activity from MHV 148 PLP2 while preserving the peptide hydrolysis and deISGylating activities of PLP2. Next, we 149 focused on comparing the activity of the mutant enzyme to its wild-type counterpart for the ability 150 to remove Flag-tagged-ubiquitin conjugated to host proteins in cultured cells (Fig. 3A) . We found 151 that in cells, wild-type PLP2 exhibits robust DUB activity and removes ubiquitin modifications 152 from multiple cellular proteins. On the other hand, the PLP2-D1772A mutant exhibits reduced 153 DUB activity, similar to that of the previously documented catalytic cysteine to alanine mutant, 154 PLP2-CA (19) . To determine if this impaired DUB activity altered the ability of PLP2 to act as an 155 interferon antagonist, we transfected cells with a RIG-I expression plasmid, an interferon-156 luciferase reporter construct, and either wild-type or mutant PLP2 plasmid and measured luciferase 157 activity at 18 hours post-transfection. In agreement with previous reports (13, 25, 31) , we find that 158 wild-type PLP2 acts as an interferon antagonist, reducing reporter activity by 50-80%. In contrast, 159 PLP2-D1772A is unable to significantly reduce interferon activation in this assay despite similar 160 expression levels of the wild-type and mutant versions of the protein (Fig. 3B ). We also evaluated 161 the protease activity of the enzymes in cells using two independent trans-cleavage assays and 162 found that the wild-type and DUB-mutant enzymes produce similar levels of cleaved products. 163 These results indicate that the D1772A substitution did not alter protease activity (Fig. 3C and D) , 164 in agreement with the in vitro kinetic results described above (Fig. 2) . Together, these studies 165 reveal that aspartic acid residue 1772 of MHV-PLP2 is important for DUB activity and interferon 166 antagonism, but not for protease activity.
167

Recombinant MHV harboring PLP2-D1772A activates an earlier IFN response in bone
168 marrow-derived macrophages. Since the D1772A substitution did not impact protease activity, 169 we reasoned that we should be able to generate recombinant virus containing this substitution, 170 thereby allowing us to determine if the mutation has any effect on viral replication kinetics and 171 interferon antagonism in the context of the live virus. We engineered the mutant virus via reverse 172 genetics (32), performed full genome sequencing to verify the genotype (2 nucleotide changes at 173 positions 5525 and 5526, resulting in D1772A substitution in the replicase polyprotein), and 174 designated the virus as DUBmut. Upon evaluating virus replication of the DUBmut virus by 175 performing a growth kinetics experiment in parallel with wild-type virus, we found that the 176 DUBmut virus replicates with essentially identical kinetics as the wild-type in a murine 177 astrocytoma cell line (DBT cells) ( Fig. 4A ). These results are consistent with previous studies of 178 coronavirus interferon antagonists, which showed in many cell lines that viral-mediated interferon 179 antagonism is not essential for virus replication (5, 6) . Regarding the other ubiquitin-interacting 180 residues identified in the structural analysis, we attempted to rescue virus with substitutions at the 181 F1812 position, but were unable to recover viable virus. These results indicate that F1812 may 182 play a critical role within the polyprotein during virus replication. We were able to recover virus 183 containing the R1803A substitution, but found that it had no detectable phenotype, which we 184 documented in our previous study (5) . Here, we focus our efforts on evaluating replication and 185 pathogenesis of the recovered DUBmut virus.
186
To determine if the impaired DUB activity of the DUBmut virus had an effect on interferon 187 antagonism, we infected primary bone marrow-derived macrophages (BMDMs) and evaluated 188 viral replication kinetics and levels of interferon mRNA and protein. We observed significant 189 activation of interferon alpha (IFN) mRNA expression ( Fig. 4A ) that is coupled with release of 190 IFNprotein into the supernatant, as detected by ELISA ( Fig. 4B ). We show that this activation 191 of IFN is dependent on expression of pattern recognition receptor MDA5 ( Fig. 4D ), in agreement 192 with previous reports (5, 6, 33) . To our surprise, we found that replication of DUBmut is not and measured viral titer in the liver and spleen at the indicated days post-infection (dpi). We 207 observed similar levels of infectious particles in young mice inoculated with a high dose of virus 208 and adult mice with a low dose at 3 and 5 dpi (data not shown), but detected reduced viral titers in 209 the spleens of young mice infected with a low dose of DUBmut virus at 3 dpi ( Fig. 5A ) and adult 210 mice inoculated with a high dose at 5 dpi ( Fig. 5B ). Similar pathology in liver sections was 211 observed at 3 and 5 dpi ( Fig. 5C ). These results indicate that the DUBmut virus is mildly attenuated 212 compared to the wild-type virus, suggesting that the DUB activity does play a role in MHV 213 pathogenesis and PLP2 is a virulence factor.
214
Discussion
215
In the present study, we aimed to investigate the roles of PLP2 DUB activity during 216 coronavirus infection. Through structure-guided mutagenesis, we identified residues of MHV 217 PLP2 that mediates its interaction with ubiquitin. By mutating the residue Asp-1772 to Ala 218 (D1772A), we found that the DUB activity of PLP2 was greatly reduced and a recombinant MHV 219 carrying this mutation (DUBmut) activated an earlier IFN response in macrophages. Although we 220 only observed a subtle attenuation of the DUBmut virus in the tested animal models, we 221 demonstrated that PLP2 DUB activity does play a role in suppressing the host immune response 222 and is a virulence trait, strengthening our earlier discoveries on SARS-CoV PLpro (4). We further 223 investigated the differences in the interferon response generated in response to WT versus 224 DUBmut virus in our companion study (Volk et al., submitted) , which further supports a role for 225 DUB activity in modulating the interferon response in macrophages.
226
The structure-guided approach used to generate the DUBmut virus allowed for 227 characterization of three different classes of mutant enzymes: Class I, deficient in both DUB and 228 deISGylating activity; Class II, deficient in deISGylating activity only; and Class III, deficient in 229 DUB activity but competent in protease and deISGylating activity. We utilized three unique 230 biochemical substrates, each with a conjugated fluorescent AMC reporter, to evoke the multi-231 functional activities of PLP2. Activity against the z-RLRGG-AMC peptide substrate represents 232 the polyprotein processing activity of MHV PLP2, while UB-AMC and ISG15-AMC stimulate 233 the deubiquitinating and deISGylating activities of the enzyme, respectively (17, 34). The kinetic 234 data for the D1772A DUBmut hydrolysis of the z-RLRGG-peptide provided in Figure 2B indicate 235 that the polyprotein processing ability of this mutant is likely not affected by the D1772A 236 substitution. The deISGylating ability of the enzyme is also not affected. In contrast, the mutant 237 enzyme's deubiquitinating activity is significantly reduced relative to wild-type, which is most 238 likely due to a lowered binding affinity for ubiquitin as the enzyme could not be saturated with 239 Ub-AMC as a substrate. 240 We can also use these structural, mutagenesis and kinetic characterization studies on MHV 241 PLP2 to guide future structure-based design studies of emerging coronaviruses, such as the newly 242 emerged novel coronavirus 2019 (nCoV-2019) (35) (36) (37) (38) . By aligning the X-ray structure of the 243 PLpro domains of SARS-CoV bound to ubiquitin (17) with the sequence of nCoV-2019 PLpro 244 ( Fig. 6A ) and comparing the differences in their residues with those of MHV PLP2 (Fig. 1E ), we 245 observe significant differences in the potential interactions between nCoV-2019 and ubiquitin. For 246 example, we found that the hydrogen bonds between MHV PLP2 R1803 and the carbonyl oxygen 
255
We were able to reproduce the enzymatic profile of the purified PLP2-D1772A mutant 256 protein when we expressed it in cell culture ( Fig. 3) . Therefore, our finding that the DUBmut virus 257 containing the PLP2-D1772A substitution activates an elevated antiviral response in macrophages 258 compared to the wild-type virus, but that this antiviral state results in only mild attenuation of 259 disease in mice relative to WT infection, was unexpected. Previous studies demonstrated that 260 ubiquitin has important roles in both the activation and the attenuation of innate antiviral pathways 261 (39); therefore, we anticipated a more remarkable phenotype for a DUB-mutant virus. We can 262 imagine several possible explanations for our findings. First, it is possible that viral DUB activity 263 found that replacing the SARS PLP2/DUB domain with a SARS-related PLP2/DUB domain 267 reduced the ability of that virus to antagonize the innate immune response. Together, this previous 268 report in conjunction with the current study support the concept that different PLP2/DUB domains 269 may have distinct effects on antagonism of the innate immune response depending on the virus 270 and the host cell type. Another possibility is that the DUB-mutant virus we generated may not have 271 been sufficiently debilitated in its DUB activity to result in altered pathogenesis. We found that it 272 was difficult to recover viable DUB-mutant viruses; indeed, this D1772A mutant was the sole 273 viable DUB-mutant representative of our many attempts. Because an elevated interferon response 274 was elicited from the DUBmut-infected cells, this mutant virus fulfilled our criteria demonstrating 275 the inactivation of an interferon antagonist. However, we speculate that if we are able to recover 276 mutants that exhibit a range of DUB activity, we may be able to more fully assess the role of DUB 277 activity as a contributor to coronaviral pathogenesis. Despite these caveats, the MHV DUB-mutant 278 generated in this study did exhibit a reproducible phenotype of eliciting an elevated interferon 279 response in infected macrophages that was associated with mild attenuation of pathogenesis with 280 reduced titers in the livers and spleens of infected mice. Overall, we conclude that DUB activity 281 is indeed a virulence trait, and contributes to the ability of MHV to modulate the host innate (BMDMs) were prepared and cultured as described previously (5). 
365
Growth kinetics 366 DBT cells or BMDMs were infected with wild-type icMHV-A59 or DUB-mutant virus at 367 a multiplicity of infection (MOI) of 1 in serum-free medium. After a one-hour incubation, the 368 inoculum was replaced with fresh, complete medium. Cell culture supernatants were collected at 369 indicated time points and titrated by plaque assay on 17Cl-1 cells. Titers were obtained from three 370 independent assays for each sample. Graphs of virus kinetics were generated using Prism software 371 (GraphPad Software).
372
Quantification of IFN production by RT-qPCR and ELISA
373
BMDMs in a 12-well plate were mock-infected or infected with MHV at a MOI of 1. At Mouse experiments 389 Evaluation of MHV pathogenesis in laboratory mouse was previously described (5, 41) . Amino acids mutated in this study are indicated with a black asterisk, the catalytic cysteine is 559 indicated by a blue asterisk, and those amino acids that bind ubiquitin and were mutated in this Amino acids mutated in this study are indicated with a black asterisk, the catalytic cysteine is indicated by a blue asterisk, and those amino acids that bind ubiquitin and were mutated in this study are boxed in green. The active site substrate binding loop also involved in binding inhibitors of SARS is shown highlighted in yellow. The sequence alignment was created using ESPript3. (A) X-ray structure of SARS-CoV PLpro-ubiquitin-aldehyde complex (blue) (PDB: 4MM3) with each of its domains labeled as finger, palm, thumb, and Ubl2. Ubiquitin-aldehyde is colored yellow. The nCoV-2019 PLpro structure (cyan) was modeled by first mutating the residues of SARS PLpro in the X-ray structure to those of nCoV-2019 PLpro based upon the sequence alignment in Figure 1E . The nCoV-2019 PLpro-Ubiquitin-aldehyde complex was then refined using the structure-factor amplitudes and initial phases of the SARS PLP-Ubiquitin aldehyde complex (PDB: 4MM3). The residues that are different between SARS-CoV PLpro and nCoV-2019 PLpro are highlighted as sticks. (B) Potential interactions between L1803 of SARS-CoV PLpro and nCoV-2019 PLpro with residue A46 of ubiquitin. (C) Predicted interaction between E1772 of SARS-CoV PLpro and nCoV-2019 PLpro and residues R42 and R72 of ubiquitin. (D) Potential interactions between residues I44, V70, and R42 of ubiquitin with residues M1812 of SARS-CoV PLpro and nCoV-2019 PLpro.
